Abstract
Spontaneous intracerebral hemorrhage (ICH) is intra-parenchymal bleeding that may lead to localized hematoma formation. The hematoma can enlarge over a period of time, and directly contribute to neurological deterioration and death. Several studies have shown a relationship between acute hypertensive response and poor prognosis among patients with ICH; however, it is somewhat unclear whether hematomal expansion, is a cause or a result of elevated blood pressure (BP). Current AHA guidelines state MAP should be maintained <130 mmHg and systolic blood pressure (SBP) <180 mmHg. Two major clinical trials demonstrating tolerability and safety of aggressive BPmanagement to BP <140 mmHg in the acute phase of ICH were the ATACH (2004-2008) and INTERACT (2005-2007) trials. ATACH II and INTERACT 2 trials are currently being conducted to demonstrate the efficacy of SBP reduction as the next step to the ATACH and INTERACT pilot trials.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 322-327 |
| Number of pages | 6 |
| Journal | Current atherosclerosis reports |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2012 |
Bibliographical note
Funding Information:Disclosure Dr. Qureshi has received funding from National Institutes of Health R0-1-NS44976-01AZ (Medication provided by ESP PHARMA) and 1U01NS062091-01A2: American Heart Association established investigator award 0840053N, and Minnesota Medical Foundation, Minneapolis, Mn.
Keywords
- ATACH
- ATACH II
- Acute hypertensive response
- Antihypertensive treatment
- Cerebral blood flow
- Cerebral perfusion pressure
- Hypertension
- INTERACT
- INTERACT 2
- Intracerebral hemorrhage
- Ischemic penumbra
- Mean arterial pressure
- Perihematoma
